This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus
by Santanu Roy
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
AMGNPositive Net Change DGXNegative Net Change TMONegative Net Change FDSPositive Net Change LNGNegative Net Change NGLNegative Net Change LRNNegative Net Change NOBLNegative Net Change URGNNegative Net Change OPRTPositive Net Change PLTRPositive Net Change UROYPositive Net Change
alt-energy business-services computers consumer-discretionary finance medical medical-devices oil-energy
Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?
by Moumi Mondal
MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.
MDTNegative Net Change ABTPositive Net Change BSXNegative Net Change
medical medical-devices
Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?
by Moumi Mondal
BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.
BSXNegative Net Change ABTPositive Net Change GMEDNegative Net Change
medical medical-devices
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
by Indrajit Bandyopadhyay
Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
BAXNegative Net Change BDXNegative Net Change ICUINegative Net Change
medical medical-devices
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
by Zacks Equity Research
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
PHGNo Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Novocure Reports Patient Data Exposure in Cybersecurity Incident
by Zacks Equity Research
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
NVCRNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.
ISRGPositive Net Change BSXNegative Net Change MDTNegative Net Change
medical medical-devices
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
by Indrajit Bandyopadhyay
BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
BTSGPositive Net Change ADUSNegative Net Change OPCHNegative Net Change
medical medical-devices
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
CORNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
by Harshit Gupta
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
IRTCNegative Net Change BSXNegative Net Change PHGNo Net Change
medical medical-devices